Abbott Laboratories $ABT Stock Sold by CX Institutional

Key Points

• CX Institutional cut its Abbott Laboratories stake by 70.3% in the third quarter, selling 66,466 shares and retaining 28,023 shares valued at approximately $2.77 million. Institutional investors overall still own 75.18% of the company.
• Analyst sentiment remains favorable: Abbott has a consensus “Moderate Buy” rating and an average price target of $119.80, with several firms recently raising targets or upgrading the stock.
• Abbott beat quarterly expectations with $1.31 in EPS and $12.59 billion in revenue, while revenue grew 13% year over year. The company also declared a quarterly dividend of $0.63 per share, representing a 2.6% annualized yield.

CX Institutional reduced its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 70.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 28,023 shares of the healthcare product maker's stock after selling 66,466 shares during the quarter. CX Institutional's holdings in Abbott Laboratories were worth $2,770,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. BlackRock Inc. grew its position in Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. State Street Corp raised its holdings in Abbott Laboratories by 2.1% during the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares in the last quarter. Capital International Investors lifted its position in Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock valued at $7,922,519,000 after purchasing an additional 1,614,706 shares during the period. J. Stern & Co. LLP boosted its holdings in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors raised its position in Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock worth $4,907,523,000 after acquiring an additional 400,400 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ABT shares. Citigroup upped their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, July 17th. BTIG Research boosted their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a report on Friday, July 17th. Weiss Ratings upgraded shares of Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, September 18th. Wolfe Research upgraded shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price target for the company in a research report on Thursday, August 13th. Finally, Robert W. Baird started coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $119.80.

Abbott Laboratories Stock Performance

Shares of ABT opened at $97.52 on Friday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $135.37. The company's 50 day simple moving average is $106.99 and its 200 day simple moving average is $98.68. The company has a market capitalization of $168.75 billion, a price-to-earnings ratio of 31.56, a PEG ratio of 1.79 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the previous year, the firm posted $1.26 EPS. Abbott Laboratories's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.6%. Abbott Laboratories's dividend payout ratio is 81.55%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Rothschild & Co Redburn upgraded Abbott from “neutral” to “buy” and raised its price target to $127 from $119. The new target implies roughly 30% upside from the referenced trading level, providing the clearest catalyst for the stock’s recent strength. Rothschild & Co Redburn upgrades Abbott Laboratories to Buy From Neutral, Adjusts PT
• Positive Sentiment: Abbott is included among low-beta healthcare stocks viewed as relatively defensive amid interest-rate uncertainty and market volatility. Its diversified healthcare portfolio and dividend profile may appeal to investors seeking stability. Low-Beta Healthcare Stocks to Buy
• Positive Sentiment: Industry forecasts point to continued growth in disposable medical sensors and biomarkers, markets that include Abbott and could support longer-term demand for its diagnostics and monitoring products. Disposable Medical Sensors Market Forecasts Growth
• Neutral Sentiment: Analysts expect Abbott’s upcoming third-quarter report to show single-digit earnings growth. The results and management outlook will be important for validating the bullish price-target revision. Abbott Laboratories Quarterly Earnings Preview
• Negative Sentiment: Abbott recently underperformed the broader market, and its price remains below the 50-day moving average, indicating lingering technical pressure despite the analyst upgrade. Abbott Sees a More Significant Dip Than the Broader Market

Abbott Laboratories Profile

Abbott Laboratories NYSE: ABT is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott's medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.